Q&A with TransCelerate’s new CEO Janice Chang: Bringing the trial infrastructure to patients

Zachary Brennan

Senior Editor

TransCelerate Biopharma is unique in the nonprofit space because it brings together more than 20 top pharma competitors and allows them to collaborate, rather than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A with TransCelerate’s new CEO Janice Chang: Bringing the trial infrastructure to patients

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Large vaccine makers stand by their investments despite US headwinds

Genentech vet launches ADC startup with $20M

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Q&A with Tran­sCel­er­ate’s new CEO Jan­ice Chang: Bring­ing the tri­al in­fra­struc­ture to pa­tients

Senior Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Q&A with TransCelerate’s new CEO Janice Chang: Bringing the trial infrastructure to patients